AI · Clinical Decision Support
A Liverpool-based medical technology company building AI-powered clinical decision support for kidney injury — designed from the outset to serve both resource-limited hospitals across sub-Saharan Africa and NHS Trusts in the United Kingdom.
Clinical Principles
Early Recognition
The earliest possible identification of kidney injury, before clinical deterioration becomes irreversible. Time is the critical variable in kidney health outcomes.
Clinician-Centred Guidance
Evidence-based, context-aware clinical guidance delivered to the right clinician at the right moment — calibrated for the setting in which they practise.
Transparent Reasoning
Every clinical recommendation is accompanied by the evidence that underpins it. Clinicians understand the reasoning — they are never asked to accept a conclusion without a basis.
Designed for Real Conditions
Built for environments with intermittent connectivity, constrained laboratory infrastructure, and diverse clinical aetiologies — not idealised conditions.
About
"In too many hospitals — on both sides of the Atlantic and across sub-Saharan Africa — patients deteriorate from an entirely treatable condition because the right information did not reach the right clinician in time. We were founded to change that."
Renalis Glofil Health is a Liverpool-based medical technology company founded with a single clinical purpose: to ensure that no patient suffers an avoidable outcome from kidney injury through failure of timely clinical intelligence. We build AI-powered clinical decision support tools that work in the settings where the burden of kidney disease is greatest — and where existing technology has failed to reach.
Our platform is designed from inception to serve both low-resource hospital environments in Nigeria and high-resource NHS and international clinical settings — not as an afterthought, but as a founding architectural principle. That dual-market credibility is our most enduring clinical and commercial advantage.
The Renalis Suite
Our suite comprises five distinct products spanning the full care continuum — from community-level alerting through to hospital clinical decision support and continuous patient monitoring. All five form a single, integrated intelligence platform — ensuring that clinical insight flows seamlessly to the right clinician, in the right setting, at the right moment.
SMS Alert System
An intelligent alerting system that connects directly to hospital laboratory systems, analyses results in real time, and delivers targeted clinical notifications to ward staff — on any mobile device, over any network. No smartphone required.
Active Development
Mobile Clinical Application
A mobile application for ward clinicians that presents patient risk information in a clear, priority-ranked interface. Fully functional without an internet connection. Designed for the hardware and network conditions found in real clinical environments.
Active Development
Hospital Clinical Decision Support
A comprehensive clinical decision support system for hospital environments. Integrates with existing laboratory and patient record infrastructure. Provides real-time clinical intelligence to clinical teams across the hospital, with full audit and governance capability built in.
Active Development
NHS & International Clinical System
A clinical decision support system built for NHS Trust environments and international hospital systems, integrated directly into existing electronic patient record workflows. Clinicians receive intelligent guidance without leaving their clinical system. Designed to meet MHRA, NHS, and international regulatory standards.
In Development
Continuous Patient Monitor
A wearable continuous monitoring device that tracks key patient physiological parameters in real time — providing clinical intelligence between scheduled laboratory measurements and ensuring that patient deterioration is detected at the earliest possible moment. Designed for intensive care environments in both Nigerian hospitals and NHS Trusts, with a target of 48-hour battery life and wireless connectivity to the clinical platform.
Hardware Prototype — In Development
Our Approach
Most medical technology is designed for well-resourced environments and adapted — imperfectly — for others. We have inverted that model. Our platform is engineered from the ground up for the clinical realities of sub-Saharan African hospitals, then extended to NHS and international settings. The result is a system that is genuinely robust wherever it is deployed.
Our AI models are trained and validated on clinical data that reflects the disease patterns, patient demographics, and resource constraints of the environments in which they operate — not transplanted from settings with entirely different clinical profiles.
The platform functions with intermittent connectivity, limited laboratory infrastructure, and basic mobile devices. Resilience is an architectural requirement, not an afterthought. The system is designed to maintain clinical utility even when the environment is not ideal.
Every design decision is made with the end regulatory submission in mind — whether that is NAFDAC approval in Nigeria, MHRA registration in the United Kingdom, or FDA clearance in the United States. Compliance is built in, not bolted on.
We do not build in isolation. Every product decision is made in active collaboration with practising clinicians at our partner institutions in Nigeria and the United Kingdom. Clinical credibility is non-negotiable.
Patient data collected in Nigeria is governed under Nigerian law and stored on Nigerian infrastructure. Patient data collected in the United Kingdom is governed under UK GDPR. We do not aggregate patient data across jurisdictions without the explicit consent frameworks required by each.
Our commercial model is designed to remain affordable in low-income settings at scale, permanently — not only at launch or during pilot phases. Sustainable pricing in every market is a condition of deployment, not a discretionary benefit.
"The greatest clinical risk in any AI health system is not that the algorithm is wrong — it is that the clinician cannot interrogate why. We will never deploy a system whose reasoning cannot be examined."
Moses Omughele — Founder & CEO
Development Programme
A disciplined, evidence-led development programme from clinical validation through to multi-market deployment and international regulatory approval.
Phase 1 — Years 1–3
Phase 2 — Years 4–6
Phase 3 — Years 7–10
Mission & Vision
Our vision is simple and absolute: a world in which no patient dies from a kidney injury that could have been detected in time. Not in London. Not in Lagos. Not anywhere that Renalis Glofil Health has the privilege of operating.
That is not a corporate aspiration. It is the clinical standard against which every decision this company makes — every design choice, every partnership, every regulatory submission — is measured.
"No patient in any hospital where Renalis Glofil Health operates should die from a kidney injury that our technology could have detected in time. That is not a mission statement. That is a clinical standard."
Moses Omughele — Founder & CEO
"We chose to build for the most under-resourced hospitals first — not because it was the easiest path to market, but because that is where the unmet clinical need is greatest and where our work will matter most."
Moses Omughele — Founder & CEO
Our Commitments
Every recommendation produced by our system is a decision-support output — never a replacement for clinical judgement. No product will be released without independent clinical validation. The clinician remains in command.
We build first for the settings most underserved by conventional medical technology — under-resourced hospitals in Nigeria, peripheral primary care, and resource-constrained clinical environments. High-income market products are extensions of that foundation, not the origin of it.
Every clinical recommendation is accompanied by the evidence that underpins it. We do not deploy opaque systems in clinical environments. Clinicians must be able to interrogate, challenge, and override every output our platform produces.
Patient data is governed under the laws of the jurisdiction in which it is collected. Data collected in Nigeria stays in Nigeria. Data collected in the United Kingdom stays in the United Kingdom. No cross-border transfer occurs without the legal frameworks to support it.
All clinical outcomes are measured against peer-reviewed benchmarks. We will publish our validation data in full. We will not make efficacy claims that we cannot defend in an international peer-reviewed journal.
Our pricing model is built to remain affordable in every market we serve — permanently, not only at launch. Commercial success and clinical access are not in conflict. We have designed the business to prove that they are not.
Clinical Partnerships
We do not build in isolation. Every product decision is grounded in active clinical partnership with practising nephrologists and hospital teams in Nigeria and the United Kingdom. Partnership is not a marketing activity — it is the scientific foundation of everything we build.
Nigeria — Anchor Clinical Partnership
We are establishing an anchor clinical partnership with a leading Nigerian Federal Teaching Hospital — one of the country's foremost academic medical institutions. This partnership will provide the clinical validation environment for our Nigerian deployment programme and anchor our regulatory submission to NAFDAC. The institution and its Principal Investigators have been identified. Formal agreements are in progress.
United Kingdom — Scientific Advisory Board
Five UK consultant nephrologists are being appointed to the Renalis Glofil Health scientific advisory board. Between them, they span AKI clinical guideline leadership, NHS critical care nephrology, clinical AI deployment in the NHS, and national renal policy. Their role is to provide independent clinical oversight of all product development and validation activities.
Funding & Growth Partners
We are in active discussions with UK health-focused pre-seed investors and have submitted applications to multiple competitive grant programmes including Innovate UK and international global health funders. Our funding strategy is deliberately non-dilutive in the early phase, preserving equity for the clinical milestones that drive valuation most significantly.
Founder & Chief Executive Officer
Leadership
Moses Omughele is the sole founder and architect of Renalis Glofil Health Ltd. His academic background spans human anatomy, international public health, data science, and business — a combination that is both unusual and directly relevant to the challenge of building clinical AI for global health settings.
He holds the clinical knowledge to understand what the system must do, the technical ability to build it, and the public health perspective to ensure it reaches the populations where it is most needed. There is no domain within this company — clinical, technical, regulatory, or commercial — that requires a different person to hold.
Renalis Glofil Health Ltd is registered in England and Wales, Companies House No. 17147097, and is headquartered in Liverpool, Merseyside.
"We are not building a product for clinicians to trust. We are building a product that earns trust — through clinical evidence, regulatory rigour, and transparent reasoning, every step of which will be published for scrutiny."
Moses Omughele — Founder & CEO
"The academic institutions that trained me — from Maiduguri to Glasgow to Liverpool — gave me a perspective that no single discipline could have. This company is the convergence of all of them."
Moses Omughele — Founder & CEO
Get in Touch
We welcome enquiries from clinical institutions, NHS Trusts, investors, regulatory bodies, and global health partners. All demonstrations are tailored to your specific context and conducted by appointment.
Thank you for your enquiry. We will review your message and respond within two business days. Please also check your junk folder.